Anti-IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis.

J Allergy Clin Immunol Glob · 2025 · PMC11683235 · PMID 39736892

Europe PMC DOI

hedged sentence

0.1325

closest p · 2.6× alpha

0.1325

boldest claim

The sentences

did not reach statistical significanceP = .1325not close (p > 0.1)

Although there was a trend to lower use of antifungal associated with anti–IL-4Ra therapy than with anti–IL-5/IL-5Ra, this difference did not reach statistical significance given a large variability in the CI (OR, 0.04; 95% CI, 0.06-2.72; P = .1325) ( Fig 1 , B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.